Midkine as a factor to counteract the deposition of amyloid β-peptide plaques: in vitro analysis and examination in knockout mice by Muramatsu1, Hisako et al.
ORIGINAL RESEARCH Open Access
Midkine as a factor to counteract the deposition
of amyloid b-peptide plaques: in vitro analysis
and examination in knockout mice
Hisako Muramatsu1
1,2,3*, Katsunori Yokoi
1, Lan Chen
1, Keiko Ichihara-Tanaka
1,3,4, Terutoshi Kimura
5,
Takashi Muramatsu
1,4
Abstract
Background: Midkine is a heparin-binding cytokine involved in cell survival and various inflammatory processes.
Midkine accumulates in senile plaques of patients with Alzheimer’s disease, while it counteracts the cytotoxic
effects of amyloid b-peptide and inhibits its oligomerization. The present study was conducted to understand the
role of midkine upon plaque formation of amyloid b-peptide.
Methods: A surface plasmon assay was performed to determine the affinity of midkine for amyloid b-peptide. The
deposition of amyloid b-peptide was compared in the brain of wild-type and midkine-deficient mice. An effect of
midkine to microglias was examined by cell migration assay.
Results: Midkine bound to amyloid b-peptide with the affinity of 160 nM. The C-terminal half bound to the
peptide more strongly than the N-terminal half, and heparin inhibited midkine from binding to the peptide.
Pleiotrophin, which has about 50% sequence identity with midkine also bound to amyloid b-peptide. The
deposition of amyloid b-peptide plaques in the cortex and hippocampus was more intense in 15-month-old
midkine-deficient mice, compared to the corresponding wild-type mice. Midkine promoted migration of microglias
in culture.
Conclusions: These results are consistent with the view that midkine attenuates the deposition of amyloid b-
peptide plaques, and thus progression of Alzheimer’s disease, by direct binding and also by promoting migration
of microglias.
Background
An accumulation of amyloid b-peptide (Ab)i np l a q u e s
in brain tissue has been proposed to be the primary
cause of the neurodegeneration in patients with Alzhei-
mer’sd i s e a s e[ 1 , 2 ] .T h i sv i e wi ss u p p o r t e db yf i n d i n g s
that anti-Ab antibodies prevent or reverse the disease in
mouse models of Alzheimer’s disease [1,3,4], although
clinical trials of anti- Ab antibodies did not give
expected results [5,6]. Therefore, factors affecting the
accumulation of Ab plaques in brain tissue are impor-
tant to the treatment and prevention of Alzheimer’s dis-
ease. This paper primarily examines the role of midkine,
a heparin-binding cytokine [7-9], in the deposition of
Ab plaques in the mouse brain.
Midkine promotes neurite outgrowth [10], the survival
of various cells including neurons [11-13] and the
migration of inflammatory leukocytes [14,15] and neu-
rons [16]. Midkine is involved in pathogenesis of malig-
nant tumors [17] and diseases with immunological
backgrounds [14,15,18-20] as well as in repair of
damaged tissue [13,21].
Midkine was found to accumulate in senile plaques in
the hippocampus of patients with Alzheimer’sd i s e a s e
[22]. All patients examined so far exhibited the phenom-
enon. Reflecting this accumulation, serum levels of mid-
kine were increased in about half of patients with
Alzheimer’s disease [23]. Midkine accumulation appears
to be present even at the early stage of the disease, since
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patients with incipient Alzheimer’s disease, who exhib-
ited normal range of the Mini-Mental State Examination
scores at the time of diagnosis and serum collection,
and later the decreased scores [23].
The accumulation of midkine in senile plaques does
not necessary mean an involvement in the etiology of
Alzheimer’s disease. Indeed, Yu et al. [24] and Monji
et al. [25] found that midkine inhibited amyloid b-fibril
formation and Ab -induced cytotoxicity in PC12 cells.
These results indicate that midkine might counteract
the actions of Ab. Thus, we performed further studies
to understand the role of midkine during the develop-
ment of Alzheimer’s disease. Firstly we examined bind-
ing properties of midkine to Ab, and also studied the
binding of pleiotrophin to Ab. Pleiotrophin, alternatively
called HB-GAM has about 50% sequence identity with
midkine and share many of the activities with midkine
[26-28]. Pleiotrophin is also deposited in senile plaques
of patients with Alzheimer’s disease [29]. Secondly, we
used mice deficient in the midkine gene to analyze the
in vivo role of midkine on accumulation of Ab.T h i r d l y
we investigated novel midkine activity, which might
influence plaque accumulation of Ab. All results indi-
cated that midkine counteracted the deposition of Ab
plaques by direct binding and promotion of migration
of microglias.
Methods
Chemicals
Midkine and amyloid b-peptide (human, 1-40) were
purchased from Peptide Institute, Osaka, Japan. Pleiotro-
phin and half molecules of midkine and pleiotrophin
were chemically synthesized as described before [30,31].
Mutant midkine proteins were produced by baculovirus
as described before [32].
Animals
Mice deficient in the midkine gene (Mdk)(MKKO) or
pleiotrophin gene (Ptn)(PTNKO) were generated as
described previously and maintained as heterozygotes by
crossing with C57BL/6 mice [33,34]. Mice deficient in
both Mdk and Ptn (DKO) were produced by crossing
Mdk+/- Ptn+/- mice. Transgenic mice with APP expres-
sion under B6SJL background (APP transgenic mice)
were purchased from Taconic, Germantown, NY. The
transgenic mice with Mdk-/- genotype were obtained by
crosses of the transgenic mice with Mdk+/- genotype,
and crosses of the progenies. All mice (2 or 15 months
old) used in the present experiments were bred and
maintained with sterilized food, water, and bedding at
the Animal Facility of the Nagoya University Graduate
School of Medicine. Animal experiments were approved
by the Committee on Animal Experiments of Nagoya
University Graduate School of Medicine under the gui-
dance set by the Ministry of Education, Culture, Sports,
Science and Technology of Japan, and in accordance
with the National Institute of Health Guide for the Care
and Use of Laboratory Animals (NIH Publications No.
80-23) revised 1996. All efforts were made to minimize
the number of animals and their suffering.
Binding Assay of midkine to Ab in the Biacore System
The binding of midkine to Ab was evaluated in the Bia-
core 3000 System. A CM5 sensor chip coated with car-
boxymethyldextran was activated by injecting a solution
(1:1) of 200 mM N-ethyl-N’-(3-dimethylaminopropyl)
carbodiimide hydrochloride and 100 mM N-hydroxysuc-
cinimide at a flow rate of 10 μl/min. A 70 μl aliquot of
Ab solution (50 μg/ml in 10 mM acetate buffer, pH 5.0)
was injected for immobilization of Ab.T h er e m a i n i n g
activated N-hydroxysuccinimide ester groups were
blocked by injecting 1M ethanolamine hydrochloride/
N a O H ,p H8 . 5 ,a n dw a s h e dw i t h1 0μlo f1MN a C l .
Human midkine (hMK)(0.62 - 20 μg/ml), hMK C-half,
hMK N-half, human pleiotrophin (hPTN), hPTN C-half,
hPTN N-half and mouse midkine mutants (5 μg/ml) in
the running buffer (10 mM HEPES-NaOH, pH 7.4, con-
taining 0.15 M NaCl and 0.0005% Tween 20) were
injected into the flow cell, and the change in resonance
units was recorded. In the inhibition assay with heparin,
hMK (5 μg/ml) and heparin (0 - 25 μg/ml) in the run-
ning buffer were injected into flow cell. Binding assays
were performed at 25°C with a constant flow rate of
10 μl/ml in both association and dissociation phases.
Immunohistochemistry and the counting of Ab deposits
The old female mice (15 months) were perfused with 4%
paraformaldehyde and the brains were excised. Tissues
were fixed in 4% paraformaldehyde, dehydrated and
embedded in paraffin. Sections were cut at a thickness
of 5 μm and serial sections were mounted on slides,
dried overnight and stored in an airtight box. Sections
were stained with hematoxylin and eosin. For Ab stain-
ing, sections were removed up from the serial slides and
treated with 0.3% H2O2 in methanol for 30 min at room
temperature, followed by 70% formic acid for 8 min at
room temperature. Being washed with water, and with
Dulbecco’s phosphate-buffered saline (PBS) 3 times, the
sections were blocked with 5% normal goat serum for
30 min and treated with a mouse monoclonal anti-Ab
antibody (6E10 or 4G8, Signet laboratories, Dedham,
MA) for 2 h at room temperature, followed by biotin-
conjugated anti-mouse IgG (IBL, Takasaki, Japan) and
Vectastain ABC standard kit (PK-6100, Vector labora-
tories, Burlingame, CA). The staining was visualized with
a diaminobenzidine tetrahydrochloride kit (Dako, Kyoto,
Japan), and the sections were lightly counterstained with
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light microscope.
Deposits of Ab with a width of more than 25 μmi n
the cerebral cortex and hippocampus were measured
and counted at magnification of × 400 using a system
microscope (BX41,Olympus), a digital camera (DP70,
Olympus) and MetaMorph Basic (Molecular Devices).
The number of sections was more than 15 per brain
and the average number of Ab plaques was calculated.
Six mice per a genotype were analyzed, except otherwise
specified.
RT-PCR
The oligonucleotide primers, forward and reverse, used
for amplification were as follows; Amyloid b precursor
protein (APP) 5’-CTGACCACTCGACCAGGTTCT-
GGG-3’ and 5’-CCGTTCTGCTGCATCTTGGAGAG
A-3’, Apolipoprotein E (ApoE) 5’-CTGACAGGATGCC-
TAGCCG-3’ and 5’-ACTGGACCCAGCTGTTCCT-3’,
presenilin 1 (Psen1) 5’-GGTGGCTGTTTTATGTC
CCAA-3’ and 5’-ACTGAAGCCACCATCATCGTT-3’,
nicastrin (Nct) 5’-ACTCATCAGATTGGCTGCCAG-3’
and 5’-TTGCCCAGTTCATTCCACAGT-3’, b-secretase
1 (Bace1) 5’-CAGTGGGACCACCAACCTTC-3’ and 5’-
TCCACCGGCCGTAGGTATTG-3’, neprilysin (Mme)
5’-GCAGCCTCAGCCGAAACTAC-3’ and 5’-TCAG-
CATCCATCCAAGTAAG-3’, insulin degrading enzyme
(Ide) 5’-GAAGACAAACGGGAATACCGTG-3’ and 5’-
TGTGTTCTCCACTGGTGAATGC-3’,a n db-actin 5’-
GTGGGCCGCTCTAGGCACCA-3’ and 5’-CGGTTG
GCCTTAGGGTTCAGGGGG-3’.
Total RNA from the brain was prepared as descried
[33]. cDNA was synthesized from 1 μgo ft h eR N A
using a SuperScript First-Strand™ Synthesis System for
RT-PCR (Invitrogen, Carlsbad,CA). After preincubation
at 94°C for 5 min, PCR was performed for 25 cycles
(b-actin), 30 cycles (APP, ApoE, Ide), or 35 cycles (Mme,
Bace-1, Psn-1) of 30 sec at 94°C, 40 sec at 60°C, and 90
sec at 72°C, and also performed for 35 cycles of 30 sec at
94°C, 40 sec at 64°C, and 90 sec at 72°C for Nct.
Culture of microglia and migration assay
Mouse primary microglias were isolated from primary
mixed glial cell cultures, which were obtained from
newborn wild-type C57BL/6 (WT) or MKKO mouse
brains using the shaking-off method as described pre-
viously [35].
The migration of microglias was assayed using Che-
motaxicell (Kurabo, Osaka, Japan) with pores 5 μmi n
diameter [14]. The lower surface of the filter was coated
with 10 μg/ml of MK or poly-D-lysine in PBS. An ali-
quot of 1.0 × 10
5 microglia cells in RPMI1640 medium
containing 0.3% BSA (100 μl) was placed in the upper
chamber. Then, 600 μl of RPMI1640 medium containing
0.3% BSA was added to the lower chamber and
incubated at 37°C for 4 h.
Statistical analysis
Data are presented as the mean ± SEM. Statistical com-
parisons were performed using Student’s t-test. P values
less than 0.05 were considered significant.
Results
Binding of midkine to Ab
Midkine inhibits the formation of amyloid b-fibril and
Ab-induced cytotoxicity in PC12 cells, and forms a com-
plex with Ab [ 2 4 , 2 5 ] .H o w e v e r ,i t sb i n d i n gt oA b had
n o tb e e ne x a m i n e di nd e t a i l .W es t u d i e dt h i sp o i n t
using the Biacore assay (Figure 1A). Midkine was found
to interact with Ab with a dissociation constant of
160 nM (Figure 1A). Then, we compared the binding
activity at a concentration of 250 nM. Since midkine is
composed of two domains, the N-terminal half and
C-terminal half [7], we examined which portion bound
to Ab, and found that the C-terminal half bound more
strongly (Figure 1B). The C-terminal half has two
heparin-binding sites [36]. The mutation of key amino
acids in either of the two sites [32] did not affect the
binding activity, while the mutation of both sites
resulted in a decrease in the binding activity (Figure 1B),
indicating that amino acid residues in or around these
heparin binding sites are involved in the binding to Ab.
This inference was consistent with the inhibitory activity
of heparin toward the binding between midkine and Ab
(Figure 1B). Pleiotrophin also bound to Ab with some-
what less activity, and its C-terminal half exhibited
much less binding activity than midkine (Figure 1 B)
Enhanced plaque deposition of Ab in the brain of MKKO
mice
Deposition of Ab plaques was observed in the cortex
and hippocampus of 15-month-old wild-type mice (WT)
with APP transgene (Figure 2A). We found that in the
brain of the transgenic mice without MK gene (MKKO),
Ab plaques were more intense: (Figure 2A). Stronger
staining and larger deposits were observed in two
MKKO. Even the total number of Ab deposit larger
than 25 μm tended to be more in the MKKO. The num-
ber was 36 and 22 in MKKO, and 22 and 19 in WT.
During the study, we incidentally observed that depos-
its of Ab plaques similar to those observed in Ab trans-
genic WT were present in 15-month-old MKKO without
transgene, although the number of the deposits were
much less (Figure 2B). These deposits were never found
in younger mice after repeated examination, but were
detected even in 15 month-old WT with further less
intensity and number. We used 6E10 antibody, which
preferentially reacts with human Ab, and cross-reacts
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body, which reacts mouse Ab more intensely, revealed
deposits also (data not shown). Thus, we concluded that
these deposits are Ab deposits produced with much less
frequency, and performed further analysis.
The total number of Ab deposit larger than 25 μm
w a ss i g n i f i c a n t l ym o r ei nM K K Oc o m p a r e dt oW T
(Figure 3A, B); the number was 3.67 ± 0.87 for WT and
7.55 ± 2.90 for MKKO. However, the effect of pleiotro-
phin deficiency was less compared to that of midkine
deficiency, and there was no statistically significant dif-
ference between WT and PTNKO. Mice deficient in
both midkine and pleiotrophin (DKO) exhibited similar
numbers of Ab p l a q u e sa sM K K Om i c e .T h ea b o v e
observation was consistent with that in the transgenic
mice and we concluded that midkine inhibited the
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Figure 1 Midkine binding to Ab. Specific interactions of midkine with Ab were examined using the Biacore system. (A), Sensorgrams for the
binding of human midkine (hMK) to Ab (left) and the calibration curve (right). Various concentrations of hMK (0.62 μg-20 μg/ml) were injected
onto an Ab- immobilized sensor chip. The arrows indicate the beginning of the association phase initiated by the injection of hMK and the
beginning of the dissociation phase initiated with the running buffer. RU, response units (B), Binding of hMK, hPTN (left) and mouse midkine
(mMK) (middle) to Ab, and inhibition of the binding of midkine to Ab by heparin (right). hMK, hMKC-half (MK-C), hMK N-half(MK-N), hPTN, hPTN
C-half (PTN-C), hPTN N-half (PTN-N), mMK, mMK mutants (m1: R78Q; m2: K83Q/K84Q; m3: R78Q/K83Q/K84Q) were injected onto an Ab-
immobilized sensor chip in concentration of 5 μg/ml. In the inhibition assay with heparin, hMK (5 μg/ml) and heparin (0-25 μg/ml) in the
running buffer were injected into the flow cell.
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not inhibit significantly.
We also examined the expression of genes related to
etiology of Alzheimer’s disease in the brain of 2- or 15-
month-old mice (Figure 4). There were no significant
differences in gene expression between WT and MKKO.
However, increased expression of amyloid precursor
protein (APP) and neprilysin (Mme) was found in the
brain of PTNKO 2 month after birth, and in the brain
of DKO both 2 and 15 months after birth.
Midkine enhances the migration of microglia cells
To understand further the reason for the increased
deposition of Ab plaques in midkine-deficient mice, we
investigated whether midkine enhances the migration of
microglia cells. These cells in the brain mediate various
inflammatory processes and are also involved in the
clearance of Ab [37]. We found that a coating with mid-
kine enhanced the migration of microglia cells intensely
compared with a coating with poly-D-lysine (Figure 5).
The migratory activity of cells from MKKO was slightly
less extensive than that of cells from WT.
Discussion
Deposition of Ab plaques in the brain of aged MKKO
was more extensive compared to aged WT. This ten-
dency was found using APP transgenic mice, and a sup-
portive evidence was obtained by examining
spontaneous deposition of a small number of Ab pla-
ques in 15-month-old mice without APP transgene.
Figure 2 Immunohistochemical staining of Ab in the mouse brain. (A) Tissue sections of the brain from APP transgenic mice (15-month-old)
were stained with mouse monoclonal anti-Ab antibody. The mice were either without midkine gene (MKKO) or with it (WT). Bar: 200 μm (B)
Two examples of immunostained Ab deposits found in the brain of 15-month-old MKKO mice without transgene. Bar: 50 μm.
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ing to the onset of Alzheimer’s disease. One basis for
midkine’s inhibition of the deposition of Ab plaques is
its binding to Ab; this binding can inhibit the polymeri-
zation of Ab [24,25].
We are aware of the fact that spontaneous deposition
of Ab p l a q u e sw a sn o tr e p o r t e di na g e dn o n t r a n s g e n i c
mice. However we should emphasize that such a plaque
deposition in a small number was first detected by
examining MKKO, and comparative studies in WT
revealed further small number of the plaque. Probably
such a small number of the plaque has been considered
to be nonspecific.
Pleiotrophin, which shares much of its activity with
midkine [7,28,29], was observed to bind Ab with some-
what decreased activity compared to midkine. Even
though expression of APP and Mme was increased in
PTNKO, PTNKO did not exhibit a significant increase
in deposition of Ab plaques. Further, DKO did not
accumulate more Ab plaques than MKKO. The most
likely explanation for this is the weaker affinity of pleio-
trophin to Ab.
We found that heparin inhibited the binding of mid-
kine to Ab. Since the mutation of all heparin-binding
sites in midkine reduced its binding to Ab,a n dt h e
C-terminal half of midkine, which has the principal
heparin-binding site [38], significantly retains the Ab
binding activity, it is likely that the binding with Ab
involves amino acids in or around the heparin-binding
sites of midkine. Thus, one possible reason for the inhi-
bition by heparin is occupation of the Ab-binding site in
midkine by heparin. In other words, heparin and Ab
may compete for a binding region on the surface of
midkine. On the other hand, as heparin and other glyco-
saminoglycans bind to Ab and promote its aggregation
[39], another reason for the inhibition by heparin is the
N
u
m
b
e
r
 
o
f
 
A
β
-
d
e
p
o
s
i
t
s
12
2
4
6
8
0
10
Genotype
WT
WT
MKKO
MKKO DKO
DKO PTNKO
PTNKO
* *
A
B
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event, it is clear that midkine and glycosaminoglycans,
which have strong affinity to each other, play opposite
roles in accumulation of Ab plaques.
That the C-terminal half of midkine is principally
responsible for binding to Ab is a key to understand the
lesser affinity of pleiotrophin to Ab compared to mid-
kine, even though both midkine and pleiotrophin
strongly bind to heparin. The different binding capabil-
ity to Ab was more evident in the C-terminal half. The
C-terminal half of midkine binds to heparin strongly,
but its N-terminal half only weakly [38]. However, both
the N-terminal and C-terminal domains of pleiotrophin
bind to heparin with similar affinities [40]. As to a struc-
tural difference of the C-terminal halves between
midkine and pleiotrophin, we are aware that a heparin-
binding site, Cluster 2, [32,36] is present in human and
mouse midkine, but absent in pleiotrophin. The struc-
tural features of the C-terminal half of midkine, which
allow strong binding to heparin, appear to cause stron-
ger binding of midkine to Ab compared to pleiotrophin.
The dissociation constant between midkine and Ab
was 160 nM. To evaluate the in vivo role of this binding,
it might be necessary to estimate the concentration of
midkine in the brain. Although midkine is not strongly
expressed in the adult brain, it is abundant in the
embryonic brain. The amount of midkine in the brain of
day 12 mouse embryos was determined to be about
20 μg per g [41]. Since staining intensity of midkine in
senile plaques was similar to that in the embryonic
brain, we infer that a similar level of midkine is locally
present in the plaques. This inference makes the disso-
ciation constant to be significant in vivo. It should also
be mentioned that the dissociation constant of midkine
and heparin determined by the same method was
159 nM [42].
Midkine, Ab, heparan sulfate proteoglycans with
heparin-like domains and other molecules coexist in the
brain tissue and senile plaques. Thus, the interactions
between midkine and Ab are affected by other molecules.
When we consider interactions between midkine, Ab and
heparan sulfate proteoglycans, the relative concentration
of heparan sulfate proteoglycans to Ab is important
because of similar levels of the affinities of heparin and
Ab to midkine. When the concentration of heparan
sulfate proteoglycans is low, the binding of Ab and mid-
kine will become prominent, and aggregation inhibitory
activity of midkine [25] may be exerted in vivo.
We also found the migration of microglias to be
enhanced by midkine. Microglias are involved in the
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Figure 4 RT-PCR analysis of the gene expression in the brain.
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(15M) of age. APP: amyloid precursor protein, ApoE: apolipoprotein
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degrading enzyme (insulysin), Mme: neprilysin. *: increased
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Figure 5 Midkine enhances the migration of microglia cells.
The migration assay was performed with filters coated with midkine
(MK) or poly-D-lysine (PDL) on the lower surface at 10 μg/ml.
Microglia cells (1x10
5 cells in 100 μl 0.3% BSA/RPMI1640) prepared
from WT (filled bars) or MKKO (open bars) newborn mice were
added to the upper chamber of a Chemotaxicell, and incubated for
4 h. Ten fields (x 400 magnification) per filter were counted to
determine the number of migrated cells. (1 field corresponds to 1/
160 of the entire surface of the filter). The values are the mean ±S.E.
per field. n = 3. *P < 0.0001, **P < 0.001.
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migration would be another reason why midkine sup-
presses accumulation of Ab. However, some caution is
required to state that enhancement of migration of
microglias by midkine contributes to suppression of the
disease progression, since there are reports that micro-
glias are involved in inflammation in the brain, and in
etiology of Alzheimer’s disease [43,44].
Conclusions
Midkine suppressed the accumulation of Ab plaques as
evidenced from the phenotype of MKKO. The basis of
this midkine activity was relatively strong binding of
midkine to Ab. Furthermore, midkine promoted the
migration of microglias. Midkine is expected to suppress
the process leading to Alzheimer’s disease.
Abbreviations
Aβ, amyloid β-peptide; APP, amyloid precursor protein; DKO, double
knockout; hMK, human midkine; hPTN, human pleiotrophin; MKKO, midkine
knockout; mMK, mouse midkine; Nct, nicastrin; PTNKO, pleiotrophin
knockout; WT, wild-type
Acknowledgements and Funding
We thank Prof. Akio Suzumura for guidance in microglia migration assay,
and Ms. Kyoko Kobori for expert technical assistance. This work was
supported in part by grants from the Ministry of Education, Culture, Sports,
Science and Technology.
Author details
1Department of Biochemistry, Nagoya University Graduate School of
Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
2Division of Disease Models, Center for Neurological Disease and Cancer,
Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku,
Nagoya, Aichi 466-8550, Japan.
3Department of Health and Nutrition, Faculty
of Psychological and Physical Science, Aichi Gakuin University, 12 Araike,
Iwasaki-cho, Nisshin, Aichi 470-0195, Japan.
4Department of Health Science,
Faculty of Psychological and Physical Science, Aichi Gakuin University, 12
Araike, Iwasaki-cho, Nisshin, Aichi 470-0195, Japan.
5Peptide Institute Inc, 4-1-
2 Ina, Minoh, Osaka 562-0015, Japan.
Authors’ contributions
HM designed all experiments, performed immunohistochemical analysis, PCR
and surface plasmon resonance and prepared significant portion of the first
draft of the manuscript, KY performed immunohistochemical analysis at the
earlier stage of this work, LC performed migration assay of microglias, KI
participated in immunohistochemical analysis and prepared midkine
mutants, TK prepared midkine half molecules and pleiotrophin, TM
continued discussion throughout the course of the work, prepared a portion
of the first draft and the major portion of the second draft. All authors
contributed to the preparation of the manuscript and approved the final
version.
Competing interests
The authors declare that they have no competing interests.
Received: 26 November 2010 Accepted: 12 January 2011
Published: 12 January 2011
References
1. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science 2002,
297:353-356.
2. Wolfe MS: Therapeutic strategies for Alzheimer’s disease. Nat Rev Drug
Discov 2002, 1:859-866.
3. Weiner HL, Frenkel D: Immunology and immunotherapy of Alzheimer’s
disease. Nat Rev Immunol 2006, 6:404-416.
4. Weksler ME, Gouras G, Relkin NR, Szabo P: The immune system, amyloid-β
peptide, and Alzheimer’s disease. Immunol Rev 2005, 205:244-256.
5. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J:
Immunotherapy for Alzheimer’s disease. Proc Natl Acad Sci USA 2004,
101(Suppl 2):14657-14662.
6. Wilcock DM, Colton CA: Anti-amiloid-β-immunotherapy in Alzheimer’s
disease: relevance of transgenic mouse models to clinical trials. J
Alzheimers Dis 2008, 15:555-569.
7. Muramatsu T: Midkine and pleiotrophin: two related proteins involved in
development, survival, inflammation and tumorigenesis. J Biochem 2002,
132:359-371.
8. Kadomatsu K, Muramatsu T: Midkine and pleiotrophin in neural
development and cancer. Cancer Lett 2004, 204:127-143.
9. Muramatsu T: Midkine, a heparin-binding cytokine with multiple roles in
development, repair and diseases. Proc Japan Acad Ser B 2010, 86:410-425.
10. Muramatsu H, Shirahama H, Yonezawa S, Maruta H, Muramatsu T: Midkine,
a retinoic acid-inducible growth/differentiation factor: immunochemical
evidence for the function and distribution. Dev Biol 1993, 159:392-402.
11. Michikawa M, Kikuchi S, Muramatsu H, Muramatsu T, Kim SU: Retinoic acid
responsive gene product, midkine, has neurotrophic functions for
mouse spinal cord and dorsal root ganglion neurons in culture. J
Neurosci Res 1993, 35:530-539.
12. Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T,
Michikawa M: Midkine inhibits caspase-dependent apoptosis via the
activation of mitogen-activated protein kinase and phosphatidylinositol
3-kinase in cultured neurons. J Neurochem 1999, 73:2084-2092.
13. Yoshida Y, Ikematsu S, Moritoyo T, Goto M, Tsutsui J, Sakuma S, Osame M,
Muramatsu T: Intraventricular administration of the neurotrophic factor
midkine ameliorates hippocampal delayed neuronal death following
transient forebrain ischemia in gerbils. Brain Res 2001, 894:46-55.
14. Horiba M, Kadomatsu K, Nakamura E, Muramatsu H, Ikematsu S, Sakuma S,
Hayashi K, Yuzawa Y, Matsuo S, Kuzuya M, Kaname T, Hirai M, Saito H,
Muramatsu T: Neointima formation in a restenosis model is suppressed
in midkine-deficient mice. J Clin Invest 2000, 105:489-495.
15. Sato W, Kadomatsu K, Yuzawa Y, Muramatsu H, Hotta N, Matsuo S,
Muramatsu T: Midkine is involved in neutrophil infiltration into the
tubulointerstitium in ischemic renal injury. J Immunol 2001,
167:3463-3469.
16. Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M:
A receptor-like protein-tyrosine phosphatase PTPζ/RPTPβ binds a
heparin-binding growth factor midkine. Involvement of arginine 78 of
midkine in the high affinity binding to PTPζ. J Biol Chem 1999,
274:12474-12479.
17. Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S,
Muramatsu T: Antisense oligodeoxynucleotide targeted to Midkine, a
heparin-binding growth factor, suppresses tumorigenicity of mouse
rectal carcinoma cells. Cancer Res 2001, 61:8486-8491.
18. Kawai H, Sato W, Yuzawa Y, Kosugi T, Matsuo S, Takei Y, Kadomatsu K,
Muramatsu T: Lack of the growth factor midkine enhances survival
against cisplatin-induced renal damage. Am J Pathol 2004, 165:1603-1612.
19. Maruyama K, Muramatsu H, Ishiguro N, Muramatsu T: Midkine, a heparin-
binding growth factor, is fundamentally involved in the pathogenesis of
rheumatoid arthritis. Arthritis Rheum 2004, 50:1420-1429.
20. Wang J, Takeuchi H, Sonobe Y, Jin S, Mizuno T, Miyakawa S, Fujiwara M,
Nakamura Y, Kato T, Muramatsu H, Muramatsu T, Suzumura A: Inhibition of
midkine alleviates experimental autoimmune encephalomyelitis through
the expansion of regulatory T cell population. Proc Natl Acad Sci USA
2008, 105:3915-3920.
21. Horiba M, Kadomatsu K, Yasui K, Lee JK, Takenaka H, Sumida A, Kamiya K,
Chen S, Sakuma S, Muramatsu T, Kodama I: Midkine plays a protective
role against cardiac ischemia/reperfusion injury through a reduction of
apoptotic reaction. Circulation 2006, 114:1713-1720.
22. Yasuhara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H, McGeer PL:
Midkine, a novel neurotrophic factor, is present in senile plaques of
Alzheimer disease. Biochem Biophys Res Commun 1993, 192:246-251.
23. Salama RH, Muramatsu H, Shimizu E, Hashimoto K, Ohgake S, Watanabe H,
Komatsu N, Okamura N, Koike K, Shinoda N, Okada S, Iyo M, Muramatsu T:
Increased midkine levels in sera from patients with Alzheimer’s disease.
Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:611-616.
Muramatsu1 et al. International Archives of Medicine 2011, 4:1
http://www.intarchmed.com/content/4/1/1
Page 8 of 924. Yu GS, Hu J, Nakagawa H: Inhibition of β-amyloid cytotoxicity by midkine.
Neurosci Lett 1998, 254:125-128.
25. Monji A, Yoshida I, Tashiro K, Hayashi Y, Matsuda K, Tashiro N: Inhibition of
Aβ fibril formation and Aβ-induced cytotoxicity by senile plaque-
associated proteins. Neurosci Lett 2000, 278:81-84.
26. Achour A, M’bika JP, Baudouin F, Caruelle D, Courty J: Pleiotrophin induces
expression of inflammatory cytokines in peripheral blood mononuclear
cells. Biochimie 2008, 90:1791-1795.
27. Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, Wang ZY: Pleiotrophin: a
cytokine with diverse functions and a novel signaling pathway. Arch
Biochem Biophys 2002, 397:162-167.
28. Rauvala H, Peng HB: HB-GAM (heparin-binding growth-associated
molecule) and heparin-type glycans in the development and placiticity
of neuron-target contacts. Prog Neurobiol 1997, 52:127-144.
29. Wisniewski T, Lalowski M, Baumann M, Rauvala H, Raulo E, Nolo R,
Frangione B: HB-GAM is a cytokine present in Alzheimer’s and Down’s
syndrome Lesions. Neuroreport 1996, 7:667-671.
30. Inui T, Bodi J, Kubo S, Nishio H, Kimura T, Kojima S, Maruta H, Muramatsu T,
Sakakibara S: Solution synthesis of human midkine, a novel heparin-
binding neurotrophic factor consisiting of 121 amino acid residues with
five disulphide bonds. J Peptide Sci 1996, 2:28-39.
31. Inui T, Nakao M, Nishio H, Nishiuchi Y, Kojima S, Muramatu T, Kimura T:
Solution synthesis and biological activity of human pleiotrophin, a novel
heparin-binding neurotrophic factor consisting of 136 amino acid
residues with five disulfide bonds. J Peptide Res 2000, 55:384-397.
32. Asai T, Watanabe K, Ichihara-Tanaka K, Kaneda N, Kojima S, Iguchi A,
Inagaki F, Muramatsu T: Identification of heparin-binding sites in midkine
and their role in neurite-promotion. Biochem Biophys Res Commun 1997,
236:66-70.
33. Muramatsu H, Zou P, Kurosawa N, Ichihara-Tanaka K, Maruyama K, Inoh K,
Sakai T, Chen L, Sato M, Muramatsu T: Female infertility in mice deficient
in midkine and pleiotrophin, which form a distinct family of growth
factors. Genes Cells 2006, 11:1405-1417.
34. Nakamura E, Kadomatsu K, Yuasa S, Muramatsu H, Mamiya T, Nabeshima T,
Fan QW, Ishiguro K, Igakura T, Matsubara S, Kaname T, Horiba M, Saito H,
Muramatsu T: Disruption of the midkine gene (Mdk) resulted in altered
expression of a calcium binding protein in the hippocampus of infant
mice and their abnormal behaviour. Genes Cells 1998, 3:811-822.
35. Suzumura A, Mezitis SGE, Gonatus NK, Silberberg DH: MHC antigen
expression on bulk isolated macrophage-microglia from newborn
mouse brain: induction of Ia antigen expression by gamma-interferon.
J Neuroimmunol 1987, 15:263-278.
36. Iwasaki W, Nagata K, Hatanaka H, Inui T, Kimura T, Muramatsu T, Yoshida K,
Tasumi M, Inagaki F: Solution structure of midkine, a new heparin-
binding growth factor. EMBO J 1997, 16:6936-6946.
37. Boche D, Nicoll JA: The role of the immune system in clearance of Aβ
from the brain. Brain Pathol 2008, 18:267-278.
38. Muramatsu H, Inui T, Kimura T, Sakakibara S, Song XJ, Maruta H,
Muramatsu T: Localization of heparin-binding, neurite outgrowth and
antigenic regions in midkine molecule. Biochem Biophys Res Commun
1994, 203:1131-1139.
39. McLaurin J, Franklin T, Zhang X, Deng J, Fraser PE: Interactions of
Alzheimer amyloid-β peptides with glycosaminoglycans effects on fibril
nucleation and growth. Eur J Biochem 1999, 266:1101-1110.
40. Raulo E, Tumova S, Pavlov I, Pekkanen M, Hienola A, Klankki E, Kalkkinen N,
Taira T, Kilpelainen I, Rauvala H: The two thrombospondin type I repeat
domains of the heparin-binding growth-associated molecule bind to
heparin/heparan sulfate and regulate neurite extension and plasticity in
hippocampal neurons. J Biol Chem 2005, 280:41576-41583.
41. Muramatsu H, Song X, Koide N, Hada H, Tsuji T, Kadomatsu K, Inui T,
Kimura T, Sakakibara S, Muramatsu T: Enzyme-linked immunoassay for
midkine and its application to evaluation of midkine levels in
developing mouse brains and sera from patients with hepatocellular
carcinomas. J Biochem 1996, 119:1171-1175.
42. Ueoka C, Kaneda N, Okazaki I, Nadanaka S, Muramatsu T, Sugahara K:
Neuronal cell adhesion mediated by the heparin-binding
neuroregulatory factor, midkine, is specifically inhibited by chondroitin
sulfate E. Structural and functional implication of the oversulfated
chondroitin sulfate. J Biol Chem 2000, 275:37407-37413.
43. Shie FS, Woltjer RL: Manipulation of microglial activation as a therapeutic
strategy in Alzheimer’s disease. Curr Med Chem 2007, 14:2865-2871.
44. Wojtera M, Sikorska B, Sobow T, Liberski PP: Microglial cells in
neurodegenerative disorders. Folia Neuropathol 2005, 43:311-321.
doi:10.1186/1755-7682-4-1
Cite this article as: Muramatsu1 et al.: Midkine as a factor to counteract
the deposition of amyloid b-peptide plaques: in vitro analysis and
examination in knockout mice. International Archives of Medicine 2011 4:1.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Muramatsu1 et al. International Archives of Medicine 2011, 4:1
http://www.intarchmed.com/content/4/1/1
Page 9 of 9